V-Wave

V-Wave Ltd. is an Israeli medical technology company founded in 2009, based in Haifa. The company specializes in developing percutaneous implantable devices aimed at treating chronic heart failure. Its main product, the V-Wave Ventura Interatrial Shunt, is a minimally invasive device designed to create a controlled interatrial shunt, helping to reduce elevated left atrial pressure in heart failure patients. This device has received Breakthrough Device Designation from the U.S. FDA and CE Marking in the European Union, highlighting its clinical significance. V-Wave's mission is to enhance treatment options for heart failure, a condition that affects millions worldwide. The company focuses on innovative interventional technologies that support patients, families, and healthcare professionals. In October 2024, V-Wave was acquired by Johnson & Johnson MedTech, which reflects the strategic importance of its technology in expanding cardiovascular care. The company primarily serves structural interventional cardiologists, heart failure specialists, hospitals, and healthcare providers, and is involved in clinical research initiatives like the RELIEVE-HF study to validate its device's effectiveness.

• Employees 43
• Founded 2009
• Annual Revenue $1500000
• Total Funding $128000000